Nuwellis Shifts Focus from REVERSE-HF Trial to Outpatient Heart Failure Growth

Minneapolis, Thursday, 17 July 2025.
Nuwellis ends its REVERSE-HF clinical trial to pivot resources toward expanding outpatient heart failure care, expecting to save $4.0 million over 2.5 years.